Alteplase for Treatment of Empyema and Complicated Parapneumonic Effusion

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the benefit to patients with empyema or complicated parapneumonic effusion (CPE) using a daily versus twice daily Alteplase regimen of two different dose strategies compared with saline placebo.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: O'Brien, Jeana D., MD, FACP, FCCP
• Collaborators: Genentech, Inc.; Scott and White Hospital & Clinic; Scott, Sherwood and Brindley Foundation; Texas A&M University
• Treatments: Tissue Plasminogen Activator

Criteria

Inclusion Criteria:

• Ability to provide written informed consent

• Age greater or equal to 18 yrs

• Presence of empyema or CPE

Exclusion Criteria:

• Active internal bleeding

• Pregnancy

• Prior enrollment in this study

• Platelet count less than 100,000/mm3

• Use of warfarin sodium if INR is greater than 1.7

• Use of heparin unless the PTT is less than 1.5 times baseline normal

• Known neurological disorders

• Current or pre-existing bleeding dyscrasia

• Known allergy to Alteplase